Evidence map›Paper›PMID 35724265›Full record

ArticleAging2022

Calreticulin nuclear translocalization alleviates CaM/CaMKII/CREB signaling pathway to enhance chemosensitivity in HDAC inhibitor-resistant hepatocellular carcinoma cells.

Yi-Sheng Liu, Yu-Chun Chang, Wei-Wen Kuo, Ming-Cheng Chen, Tso-Fu Wang, Tung-Sheng Chen, Yueh-Min Lin, Chi-Cheng Li, Po-Hsiang Liao, Chih-Yang Huang

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Aging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Calreticulin as a marker and therapeutic target for cancer.Clinical and experimental medicine · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 9 institutions in 1 country.

Yi-Sheng LiuDivision of Hematology and Oncology, Department of Medicine, Kaohsiung Armed Forces General Hospital, Kaohsiung 802, Taiwan.
Yu-Chun ChangCardiovascular and Mitochondrial Related Disease Research Center, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien 970, Taiwan.
Wei-Wen KuoDepartment of Biological Science and Technology, College of Life Sciences, China Medical University, Taichung 406, Taiwan.
Ming-Cheng ChenDepartment of Surgery, Division of Colorectal Surgery, Taichung Veterans General Hospital, Taichung 407, Taiwan.
Tso-Fu WangDepartment of Hematology and Oncology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, School of Medicine Tzu Chi University, Hualien 97004, Taiwan.
Tung-Sheng ChenSchool of Life Science, National Taiwan Normal University, Taipei 116, Taiwan.
Yueh-Min LinSchool of Medicine, Chung Shan Medical University, Taichung 402, Taiwan.
Chi-Cheng LiCenter of Stem Cell and Precision Medicine, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien 970, Taiwan.
Po-Hsiang LiaoDivision of General Surgery, Department of Surgery, Shuang Ho Hospital, Taipei Medical University, New Taipei City 235, Taiwan.
Chih-Yang HuangCardiovascular and Mitochondrial Related Disease Research Center, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien 970, Taiwan.
Tzu Chi Foundation · TWAsia University · TWChina Medical University · TWChung Shan Medical University · TWNational Defense Medical Center · TWNational Taiwan Normal University · TWNational Yang Ming Chiao Tung University · TWTaipei Medical University-Shuang Ho Hospital · TWTzu Chi University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Calreticulin (CRT) is located in the endoplasmic reticulum (ER), it helps proteins fold correctly inside the ER, and acts as a modulator of Ca

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsApoptosisCalcium-Calmodulin-Dependent Protein Kinase Type 2CalreticulinCell NucleusEndoplasmic Reticulum StressHistone Deacetylase InhibitorsHumansSignal TransductionCalcium-Calmodulin-Dependent Protein Kinase Type 2CalreticulinHistone Deacetylase InhibitorscalreticulinchemosensitivityHDACis-resistant cellshepatocellular carcinoma

Identifiers

PMID35724265
PMCPMC9271289
OpenAlexW4283171745

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.